Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A single but durable stable disease sends the microcap's stock up 730%.
